EZH2 and familial pancreatic carcinoma: Intriguingly, several epigenetic regulators (e.g., Setdb1, Asf1a, Ezh2, Kdm3a) were screened out with cell‐intrinsic effects on tumor immunogenicity or sensitivity to immunotherapy, raising the possibility that epigenetic therapy could enhance the efficacy of immunotherapy.[3, 22] However, little is known about how epigenetic regulators contribute to immune escape in pancreatic cancer.